-
Ruthenium Red in Mechanotransduction Assays
2026-09-14
Ruthenium Red is a versatile Ca2+ transport inhibitor for testing whether calcium flux contributes to mechanically induced autophagy. This article translates cytoskeleton-dependent findings into a rigorous assay-design framework while distinguishing established evidence from testable mechanistic extensions.
-
JIB-04 Targets Colorectal Cancer Stem Cells
2026-09-13
The reference study identifies JIB-04 as a pan-selective Jumonji-family histone demethylase inhibitor that preferentially suppresses colorectal cancer stem cell properties. Using tumorsphere, molecular, and tumorigenicity assays, the authors connect JIB-04 activity with reduced Wnt/β-catenin signaling, providing a mechanistic framework for targeting relapse-associated colorectal cancer cell populations.
-
Glutamine Metabolism in Hepatic Stellate Cells
2026-09-12
The reference study identifies the SIRT4–GDH metabolic axis as a regulator of hepatic stellate cell activation and liver fibrosis. By combining pharmacological GDH inhibition with SIRT4 overexpression in cellular and animal models, the authors show that restricting glutamate conversion to α-ketoglutarate can reduce fibrogenic activity.
-
Erlotinib and SCUBE3: Mapping Resistance at EGFR
2026-09-12
SCUBE3 links extracellular signaling, EGFR activity, therapy resistance, and immune suppression. This thought-leadership guide explains how Erlotinib can help translational researchers test the EGFR-dependent component of that biology while preserving a clear distinction between pathway inhibition and direct SCUBE3 neutralization.
-
X-Gal: From Clone Selection to Translational Insight
2026-09-11
X-Gal is more than a blue-white colony screening reagent: it is a practical control point for construct quality, reporter validation, and translational decision-making. This article connects the enzymatic logic of 5-bromo-4-chloro-indolyl-β-D-galactopyranoside with emerging insights into iRhom2, ADAM17, olfactory receptors, and activity-dependent adaptation.
-
BAPTA: A Causal Tool for Calcium Signaling
2026-09-11
Explore how BAPTA functions as a calcium chelator for causal calcium signaling studies, with a focused analysis of IP3R/Ca2+/STAT3-dependent apoptosis. This guide translates recent toxicology findings into better assay design, controls, and interpretation.
-
YC-1: A Decision Framework for Hypoxia Assays
2026-09-10
YC-1 is a dual-action sGC activator and HIF-1α research probe for cancer biology. This guide presents an assay-triangulation framework that separates hypoxia signaling, cGMP effects, fluorescence artifacts, and cell-death outcomes.
-
Bradykinin B2 Receptors and Ileum Peristalsis
2026-09-10
Chan and Rudd showed that bradykinin inhibits the peristaltic reflex in the isolated guinea pig ileum through B2, rather than B1, kinin receptors. Their agonist–antagonist design links receptor pharmacology to a functional motility endpoint and provides a useful framework for studying neurogastrointestinal signaling.
-
Persistent rDNA Lesions and PML-Nucleolar Compartments
2026-09-09
The reference study shows that topological stress and RNA polymerase I inhibition generate persistent lesions in ribosomal DNA that recruit PML into nucleolar associations. By combining genotoxic-stress experiments with locus-specific I-PpoI cleavage and repair-factor perturbation, the work connects rDNA damage processing, incomplete homologous recombination, and cellular senescence.
-
Tat, EZH2, and HIV Latency in Astrocytes
2026-09-09
Liu and colleagues showed that HIV Tat expression increases EZH2-associated H3K27me3 and promotes latent infection in astrocytes. The study links viral protein expression with MeCP2 and EZH2 regulation, while using GSK126 pharmacology to implicate H3K27 methylation in latency control.
-
IDO1 Blockade Activates Tumor-Protective JAK2/STAT3
2026-09-08
The reference study shows that pharmacological inhibition of IDO1 can activate antitumor immune populations while simultaneously inducing an IL-6–JAK2–STAT3 survival response in tumor cells. Its single-cell analysis provides a mechanistic explanation for why immune activation after IDO1 blockade may not translate into therapeutic benefit and supports testing pathway-directed combinations.
-
GANT61: A GLI Inhibitor for Cancer Research
2026-09-08
GANT61 is a GLI inhibitor that suppresses GLI1/2-dependent transcription at the distal Hedgehog signaling pathway. Product and preclinical evidence supports its use for GLI-mediated transcription inhibition, cancer research, and tumor growth suppression, while immune-checkpoint applications remain mechanistically informative but experimentally distinct.
-
Fumagillin Against Azumiobodo hoyamushi
2026-09-07
The reference study systematically compared 20 compounds against Azumiobodo hoyamushi, the protozoan associated with soft tunic syndrome in cultured Halocynthia roretzi. Fumagillin showed moderate 24-hour antiparasitic activity in vitro, while formalin and chlorine dioxide produced the clearest reduction in parasite burden in experimentally infected ascidians.
-
KX2-391 Dihydrochloride: From Mechanism to Translation
2026-09-05
KX2-391 dihydrochloride, also known as Tirbanibulin dihydrochloride, illustrates how dual Src and tubulin pharmacology can support a more integrated translational strategy. This article connects pathway biology, oncology and virology assays, exposure considerations, clinical relevance, and study-design decisions while distinguishing established evidence from forward-looking research opportunities.
-
Escitalopram: Phenotype-Aware Assay Design
2026-09-05
Escitalopram and Lexapro are widely used probes in serotonergic research, but clinical phenotype can determine which assay endpoints are most informative. This article connects SERT pharmacology with a post-hoc anxious-depression analysis to improve assay interpretation and reproducibility.